BeStock  
Stocks › Biotechnology › ELVN

Enliven Therapeutics ELVN

US equityMarket cap rank #2338Biotechnology
$46.53 +$0.12 (+0.26%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $46.53 0.00%
Open$46.05
Prev close$46.41
Day range$45.64 – $47.83
Volume933.6K
Market cap$3.42B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$36.05M-43.6% YoY
Net profit-$27.70M-37.5% YoY
Diluted EPS-$0.36-12.5% YoY
Free cash flow-$12.65M+4.7% YoY
Operating cash flow-$12.56M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-23.2MDec '24$-28.5MMar '25$-25.3MJun '25$-20.1MSep '25$-29.7MDec '25$-23.6MMar '26$-32.5MJun '26$-27.7MSep '26

Diluted EPS by quarter

-0.46Dec '24-0.57Mar '25-0.49Jun '25-0.32Sep '25-0.48Dec '25-0.38Mar '26-0.49Jun '26-0.36Sep '26

Free cash flow by quarter

$-17.2MDec '24$-24.1MMar '25$-17.2MJun '25$-13.3MSep '25$-15.8MDec '25$-19.3MMar '26$-18.6MJun '26$-12.6MSep '26

Annual revenue

$0.0FY20$0.0FY21$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-16.8%
Return on assets-16.4%
Return on invested capital-20.0%
Current ratio45.95
Liabilities / assets2.3%
Cash & investments$884.35M
Total debt$805,000.00
Net cash (debt)$883.55M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $36.05M $37.21M $27.82M $119.66M $34.29M
Selling and Admin Expenses $8.02M $8.21M $7.14M $33.80M $13.04M
-General & Admin Expense $8.02M $8.21M $7.14M $33.80M $13.04M
Research & Development $28.02M $29.00M $20.69M $85.86M $21.25M
Operating Profit -$36.05M -$37.21M -$27.82M -$119.66M -$34.29M
Net Non-Operating Interest Income (Expense) $8.35M $4.73M $4.20M $16.01M $4.62M
Non-Operating Interest Income $8.35M $4.73M $4.20M $16.01M $4.62M
Other Income (Expense) -$11,000.00 -$8,000.00 – -$49,000.00 $0.00
Other Non-Operating Income (Expenses) -$11,000.00 -$8,000.00 – -$49,000.00 $0.00
Pretax Profit -$27.70M -$32.49M -$23.63M -$103.69M -$29.67M
Net Profit -$27.70M -$32.49M -$23.63M -$103.69M -$29.67M
Profit from Continuing Operations -$27.70M -$32.49M -$23.63M -$103.69M -$29.67M
Net Income to Parent Company -$27.70M -$32.49M -$23.63M -$103.69M -$29.67M
Net Income to Common Stockholders -$27.70M -$32.49M -$23.63M -$103.69M -$29.67M
Basic EPS -$0.36 -$0.49 -$0.38 -$1.83 -$0.48
Diluted EPS -$0.36 -$0.49 -$0.38 -$1.83 -$0.48
Special Income (Charges) – – – $0.00 $0.00
-Less:Restructuring and Mergern & Acquisition – – – $0.00 $0.00
Tax – – – $0.00 $0.00

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $897.23M $910.22M $464.85M $476.17M $476.17M
Total Current Assets $894.76M $907.34M $463.14M $474.88M $474.88M
Cash and Cash Equivalents & Short-Term Investments $884.35M $895.16M $452.40M $462.62M $462.62M
-Cash and Cash Equivalents $151.67M $135.51M $132.18M $98.90M $98.90M
-Short Term Investments $732.68M $759.65M $320.22M $363.73M $363.73M
Other Current Assets $10.41M $12.18M $10.74M $12.26M $12.26M
Total Non-Current Assets $2.47M $2.88M $1.72M $1.29M $1.29M
Net PPE $1.51M $1.64M $310,000.00 $417,000.00 $417,000.00
-Gross PPE $1.77M $1.89M $553,000.00 $646,000.00 $646,000.00
-Accumulated Depreciation -$263,000.00 -$250,000.00 -$243,000.00 -$229,000.00 -$229,000.00
Non-Current Deferred Assets $0.00 $0.00 $217,000.00 $217,000.00 $217,000.00
Other Non-Current Assets $962,000.00 $1.24M $1.19M $656,000.00 $656,000.00
Total Liabilities $20.28M $15.07M $11.49M $16.57M $16.57M
Total Current Liabilities $19.47M $14.16M $11.49M $16.57M $16.57M
Payables $2.73M $371,000.00 $1.64M $2.16M $2.16M
-Accounts Payable $2.73M $371,000.00 $1.64M $2.16M $2.16M
Current Accrued Expenses $10.75M $10.03M $7.18M $9.36M $9.36M
Short-Term Debt and Capital Lease Obligation $510,000.00 $597,000.00 $302,000.00 $399,000.00 $399,000.00
-Current Capital Lease Obligation $510,000.00 $597,000.00 $302,000.00 $399,000.00 $399,000.00
Other Current Liabilities $174,000.00 $133,000.00 $107,000.00 $351,000.00 $351,000.00
Total Non-Current Liabilities $805,000.00 $913,000.00 $0.00 $0.00 $0.00
Long Term Debt and Capital Lease Obligation $805,000.00 – – – –
-Long Term Capital Lease Obligation $805,000.00 – – – –
Total Equity $876.95M $895.15M $453.37M $459.60M $459.60M
Stockholders' Equity $876.95M $895.15M $453.37M $459.60M $459.60M
Capital Stock $74,000.00 $73,000.00 $61,000.00 $59,000.00 $59,000.00
-Common Stock $74,000.00 $73,000.00 $61,000.00 $59,000.00 $59,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $1.31B $1.30B $824.48M $806.37M $806.37M
Retained Earnings -$430.98M -$403.28M -$370.79M -$347.17M -$347.17M
Gains/Losses Not Affecting Retained Earnings -$3.51M -$1.91M -$382,000.00 $334,000.00 $334,000.00
Other Non-Current Liabilities – $913,000.00 – – –
Restricted Cash – – – $0.00 $0.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$12.56M -$18.53M -$19.29M -$70.30M -$15.84M
Net cash flow from continuing operations -$12.56M -$18.53M -$19.29M -$70.30M -$15.84M
Net Income from Continuing Operations -$27.70M -$32.49M -$23.63M -$103.69M -$29.67M
Depreciation & Depletion & Amortization $13,000.00 $7,000.00 $14,000.00 $263,000.00 $46,000.00
Other Non-Cash Items $196,000.00 $126,000.00 $93,000.00 $353,000.00 $92,000.00
Change in Working Capital $7.95M -$605,000.00 -$3.43M -$1.12M $1.22M
-Change in Prepaid Assets $2.06M -$2.16M $1.65M -$1.11M -$694,000.00
-Change in Payables and Accrued Expense $6.09M $1.68M -$4.98M $321,000.00 $2.00M
-Change in Other Current Liabilities -$196,000.00 -$129,000.00 -$97,000.00 -$337,000.00 -$91,000.00
Net cash flow from investing $26.33M -$441.57M $42.53M -$173.84M $12.38M
Net Cash Flow from Continuing Investing Activities $26.33M -$441.57M $42.53M -$173.84M $12.38M
Net PPE Purchase and Sale -$94,000.00 -$99,000.00 $0.00 $55,000.00 $213,000.00
Net Investment Purchase and Sale $26.42M -$441.47M $42.53M -$173.90M $12.17M
Financing Cash Flow $2.39M $463.42M $10.05M $218.87M $623,000.00
Net Cash Flow from Continuing Financing Activities $2.39M $463.42M $10.05M $218.87M $623,000.00
Net Common Stock Issuance -$666,000.00 – – $216.17M $0.00
Proceeds from Stock Option Exercised $3.05M $29.94M $10.05M $2.92M $721,000.00
Ending Cash Balance $151.67M $135.51M $132.18M $98.90M $98.90M
Net Change in Cash $16.16M $3.32M $33.29M -$25.28M -$2.84M
Beginning Cash Balance $135.51M $132.18M $98.90M $124.17M $101.73M
Free Cash Flow -$12.65M -$18.63M -$19.29M -$70.46M -$15.84M
Gain/Loss from Continuing Operations – – – $106,000.00 –
Net Other Financing Charges – – – -$217,000.00 -$98,000.00

Discussion

No comments yet — be the first to weigh in on ELVN.

Sign in to join the discussion.

Scroll to Top